10 completed, 3 terminated, 1 unknown, 1 withdrawn. 15 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 15 | Completed 10, Terminated 3, Unknown 1, Withdrawn 1 |
| Phase 1 | 2 | Completed 2 |
| Phase 3 | 1 | Unknown 1 |
Follow QLT Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of the Effects of Oral QLT091001 in Adults With Impaired Dark Adaptation QLT091001, Placebo - Impaired Dark Adaptation | Phase 2 | Completed | QLT Inc. | 43 | 2013-11-01 | 2015-07-14 |
| A Study of the L-PPDS With Adjunctive Xalatan® Eye Drops in Subjects With OH or OAG Latanoprost Punctal Plug Delivery System, Xalatan - Ocular Hypertension, Open-Angle Glaucoma | Phase 2 | Completed | Mati Therapeutics Inc. | 15 | 2009-12-01 | 2014-01-10 |
| A Phase 2 Study of Punctal Placement of the Latanoprost Punctal Plug Delivery System (L-PPDS) Latanoprost - Open-Angle Glaucoma, Ocular Hypertension | Phase 2 | Completed | Mati Therapeutics Inc. | 32 | 2009-01-01 | 2013-09-19 |
| Reduced Fluence Visudyne-Anti-VEGF-Dexamethasone In Combination for AMD Lesions (RADICAL) verteporfin, ranibizumab, dexamethasone - Choroidal Neovascularization, Macular Degeneration | Phase 2 | Completed | QLT Inc. | 162 | 2007-07-01 | 2011-06-02 |
| Second Line Therapy to Treat Age-related Macular Degeneration (AMD) for Patients Not Responding Well to Lucentis Therapy by Itself Visudyne, Lucentis, Dexamethasone - Age Related Macular Degeneration | Phase 2 | Withdrawn | Vitreous -Retina- Macula Consultants of New York | 2007-01-01 | 2017-08-23 | |
| TAC-PF, Avastin® in Combination With Photodynamic Therapy to Treat Age Related Macular Degeneration Avastin, Photodynamic Therapy (PDT), Preservative-Free Triamcinolone Acetonide (TAC-PF) - Age-Related Macular Degeneration | Phase 2 | Terminated | National Eye Institute (NEI) | 100 | 2007-01-01 | 2010-03-24 |
| Combination Therapy for Age-Related Macular Degeneration. Avastin (Bevacizumab), Bevacizumab - Age Related Macular Degeneration | Phase 2 | Completed | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 103 | 2006-09-01 | 2011-09-28 |
| A Phase II, Randomized, Cross-Over, Vehicle-Controlled, Double-Blind, Multicenter Study of the Safety, Pharmacodynamics, and Preliminary Efficacy of GHRP-1/AG in Subjects With ESRD on Hemodialysis GHRP-1/AG 70 mg depot in ESRD, Placebo - End Stage Renal Disease | Phase 2 | Terminated | QLT Inc. | 3 | 2006-09-01 | 2011-04-04 |
| Triple Therapy - PDT Plus IVD and Intravitreal Ranibizumab Versus Lucentis Monotherapy to Treat Age-Related Macular Degeneration ranibizumab, dexamethasone and verteporfin, Ranibizumab - Age Related Macular Degeneration | Phase 2 | Completed | Bay Area Retina Associates | 60 | 2006-08-01 | 2010-05-27 |
| Photodynamic Therapy (PDT) for Lower Urinary Tract Symptoms (PLUS) Lemuteporfin for injection, Transurethral drug delivery system, Transurethral light delivery system - Prostatic Hyperplasia | Phase 2 | Terminated | QLT Inc. | 180 | 2005-05-01 | 2006-10-03 |
| Triamcinolone Acetonide as an Adjunctive to VPDT in ARMD. Triamcinolone Acetonide - Age-Related Macular Degeneration | Phase 2 / Phase 3 | Unknown | Canadian Retinal Trials Group | 120 | 2004-01-01 | 2007-07-30 |
| Study Of Combined VISUDYNE Therapy With Kenalog In CNV Secondary To Age-Related Macular Degeneration Visudyne, Kenalog - Age-Related Macular Degeneration | Phase 2 | Completed | Manhattan Eye, Ear & Throat Hospital | 106 | 2003-10-01 | 2007-07-12 |
| Dose Escalation Study With QLT0074 for Benign Prostatic Hyperplasia QLT0074, Photodynamic therapy - Benign Prostatic Hyperplasia | Phase 1 / Phase 2 | Completed | QLT Inc. | 2003-03-01 | 2012-05-23 | |
| Phase II Study to Evaluate Tariquidar (XR9576), a Selective MDR-1 Inhibitor, in Chemotherapy Resistant Advanced Breast Cancer Chemotherapy - Breast Neoplasms | Phase 2 | Completed | QLT Inc. | 30 | 2001-11-01 | 2012-05-23 |
| Photodynamic Therapy in Treating Patients With Stage III or Stage IV Melanoma Detox-B adjuvant, verteporfin - Melanoma (Skin) | Phase 1 / Phase 2 | Completed | QLT Inc. | 2000-10-01 | 2013-11-06 |
Macular Degeneration (7) · Choroidal Neovascularization (2) · Glaucoma, Open-Angle (2) · Ocular Hypertension (2) · Prostatic Hyperplasia (2) · Breast Neoplasms (1) · Glaucoma (1) · Kidney Failure, Chronic (1) · Lower Urinary Tract Symptoms (1) · Malnutrition (1) · Melanoma (1) · Retinal Degeneration (1) · Vision Disorders (1)
Verteporfin (5) · Dexamethasone (3) · Photochemotherapy (3) · Ranibizumab (3) · Bevacizumab (2) · Latanoprost (2) · Triamcinolone Acetonide (2) · Drug Therapy (1) · Injections (1) · QLT0074 (1) · detox adjuvant (1) · lemuteporfin (1) · retinol acetate (1)
United States (12) · Canada (6)
Graeme R Boniface (2) · Oscar Cuzanni, MD, MSc (2) · Allen Ho, MD (1) · Andrew Strong, Ph.D (1) · David A Maberley, M.D. (1) · Graeme Boniface, PhD (1) · Graeme R. Boniface, PhD (1) · Henry Hudson, MD (1) · Karl G Csaky, MD, PhD (1) · Oscar Cuzzani, MD (1) · Richard F. Spaide, MD (1) · Subhransu K Ray, M.D., Ph.D. (1) · Sushanta Mallick, Ph.D MBA (1) · Thomas G. Sheidow, MD (1)